Weight and Healthcare • 439 implied HN points • 20 Mar 24
- Eli Lilly and other pharmaceutical companies are focused on lobbying for insurance coverage of weight loss drugs, pushing for the idea of higher-weight bodies as a 'disease' worth medicating.
- The FDA approval for weight loss drugs like Zepbound requires different criteria based on BMI, raising concerns about the risk assessments being tied to body size.
- Pharmaceutical companies like Eli Lilly prioritize shareholder interests over customer concerns, raising questions about the true motivations behind their actions.